Contouring With Neuromodulators.
Journal
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
ISSN: 1524-4725
Titre abrégé: Dermatol Surg
Pays: United States
ID NLM: 9504371
Informations de publication
Date de publication:
01 Sep 2024
01 Sep 2024
Historique:
medline:
29
8
2024
pubmed:
29
8
2024
entrez:
28
8
2024
Statut:
ppublish
Résumé
Botulinum toxins, originally used for facial rejuvenation, have emerged as a promising tool for sculpting and refining contours for both the face and body. The peer-reviewed literature on neuromodulator contouring treatments was analyzed, with a particular emphasis on studies and case reports involving the use of botulinum toxin type A. Modification of face, neck, shoulder, arm, and calf contour has been reported. Treatment and dosing protocols vary with the strength and depth of the target muscle. Regional effects of neuromodulator treatment begin to appear approximately 2 weeks after injection and are often most prominent at the 70- to 90-day time point. Although treatments are generally well tolerated, short-term muscle weakness and other side effects may occur. The use of neuromodulators to enhance facial and body contours has demonstrated efficacy, but further research is needed to validate their use and explore the full potential of this intervention through larger randomized controlled trials. The application of neuromodulators as a minimally invasive tool to address the rising demand for nonsurgical body sculpting represents a promising frontier in aesthetics.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Botulinum toxins, originally used for facial rejuvenation, have emerged as a promising tool for sculpting and refining contours for both the face and body.
METHODS
METHODS
The peer-reviewed literature on neuromodulator contouring treatments was analyzed, with a particular emphasis on studies and case reports involving the use of botulinum toxin type A.
RESULTS
RESULTS
Modification of face, neck, shoulder, arm, and calf contour has been reported. Treatment and dosing protocols vary with the strength and depth of the target muscle. Regional effects of neuromodulator treatment begin to appear approximately 2 weeks after injection and are often most prominent at the 70- to 90-day time point. Although treatments are generally well tolerated, short-term muscle weakness and other side effects may occur.
CONCLUSION
CONCLUSIONS
The use of neuromodulators to enhance facial and body contours has demonstrated efficacy, but further research is needed to validate their use and explore the full potential of this intervention through larger randomized controlled trials. The application of neuromodulators as a minimally invasive tool to address the rising demand for nonsurgical body sculpting represents a promising frontier in aesthetics.
Identifiants
pubmed: 39196842
doi: 10.1097/DSS.0000000000004345
pii: 00042728-202409001-00020
doi:
Substances chimiques
Botulinum Toxins, Type A
EC 3.4.24.69
Neurotransmitter Agents
0
Neuromuscular Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
S97-S102Informations de copyright
Copyright © 2024 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.
Références
American Society for Dermatologic Surgery (ASDS). 2023 Consumer Survey on Cosmetic Dermatologic Procedures. Available from: https://www.asds.net/medical-professionals/practice-resources/consumer-survey-on-cosmetic-dermatologic-procedures. Accessed March 24, 2024.
Choe SW, Cho WI, Lee CK, Seo SJ. Effects of botulinum toxin type A on contouring of the lower face. Dermatol Surg 2005;31:502–8;discussion 507–8.
Wu Y, Zeng D, Wu S. Botulinum toxin type A for the treatment of masseter muscle prominence in Asian populations. Aesthet Surg J Open Forum 2023;5:ojad005.
Liew S, Dart A. Nonsurgical reshaping of the lower face. Aesthet Surg J 2008;28:251–7.
Brin MF, Carruthers J, Liew S, et al. Safety and efficacy of onabotulinumtoxinA for treatment of masseter muscle hypertrophy: results from a phase 2 dose-escalation study [poster]. Presented at: International Congress of the International Neurotoxin Association, January 16–19, 2019, Copenhagen, Denmark.
Sun J, Wu Y, Chen S, Humphrey S, et al. OnabotulinumtoxinA Efficacy and Safety in the Treatment of Masseter Muscle Prominence: 6-Month Results From a Phase 3, Randomized, Placebo-Controlled, Multiregional Study. (Conference presentation abstract). AMWC Monaco; 2024.
Jung GS. Temporalis muscle reduction using botulinum toxin type A for a desirable upper face circumference. Facial Plast Surg 2019;35:559–60.
Yi KH, Lee HJ, Hur HW, Seo KK, et al. Guidelines for botulinum neurotoxin injection for facial contouring. Plast Reconstr Surg 2022;150:562e–71e.
Chen Z, Chen Z, Liu W, Wei Z, et al. Efficacy and safety of botulinum toxin type A in the treatment of benign parotid hypertrophy: a prospective study. Plast Reconstr Surg 2022;150:979e–86e.
Jeong WS, Hong DW, Ahn TJ, Han HH. The volumetric effect of botulinum toxin type A injection on the parotid gland: a randomized controlled trial. Plast Reconstr Surg 2024;153:337–43.
Anand C. Facial contouring with fillers, neuromodulators, and lipolysis to achieve a natural look in patients with facial fullness. J Drugs Dermatol 2016;15:1536–42.
Yin Y, Li T, Wang C, Ma Q, et al. Treatment of facial flaccidity and sagging after botulinum toxin A injection into the masseter. Plastic Reconstr Surg 2023;151:521–5.
Han HS, Park JW, Youn CS, Ahn JY, et al. Validation of the novel masseter muscle hypertrophy scale in Asian population. J Cosmet Dermatol 2021;20:1948–50.
Rispoli DZ, Camargo PM, Pires JL Jr, Fonseca VR, et al. Benign masseter muscle hypertrophy. Braz J Otorhinolaryngol 2008;74:790–3. Erratum in: Braz J Otorhinolaryngol. 2008 Nov-Dec;74(6):949.
Moore AP, Wood GD. The medical management of masseteric hypertrophy with botulinum toxin type A. Br J Oral Maxillofac Surg 1994;32:26–8.
To EW, Ahuja AT, Ho WS, King WW, et al. A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement. Br J Plast Surg 2001;54:197–200.
Sirisuthivoranunt S, Wongdama S, Phumariyapong P, Nokdhes YN, et al. Comparative study on the duration and efficacy of various botulinum toxin type A injections for reducing masseteric muscle bite force and treating facial wrinkles. Dermatol Ther (Heidelb) 2024;14:1315–25.
Yeh YT, Peng JH, Peng HP. Literature review of the adverse events associated with botulinum toxin injection for the masseter muscle hypertrophy. J Cosmet Dermatol 2018;17:675–87.
Peng HP, Peng JH. Complications of botulinum toxin injection for masseter hypertrophy: incidence rate from 2036 treatments and summary of causes and preventions. J Cosmet Dermatol 2018;17:33–8.
Lee HJ, Kang IW, Seo KK, Choi YJ, et al. The anatomical basis of paradoxical masseteric bulging after botulinum neurotoxin type A injection. Toxins (Basel) 2016;9:14.
Kwon JS, Kim ST, Jeon YM, Choi JH. Effect of botulinum toxin type A injection into human masseter muscle on stimulated parotid saliva flow rate. Int J Oral Maxillofac Surg 2009;38:316–20.
Yi KH, Choi YJ, Lee JH, Hu H, et al. Anatomical considerations for the injection of botulinum neurotoxin in shoulder and arm contouring. Aesthet Surg J 2024;44:319–26.
Chen W, Zhang X, Xu Y, Xu Z, et al. Ultrasound-guided five-point injection of botulinum toxin for patients with trapezius hypertrophy. J Orthop Surg Res 2021;16:634.
Bae JH, Lee JS, Choi DY, Suhk J, et al. Accessory nerve distribution for aesthetic botulinum toxin injections into the upper trapezius muscle: anatomical study and clinical trial: reproducible BoNT injection sites for upper trapezius. Surg Radiol Anat 2018;40:1253–9.
Zhou RR, Wu HL, Zhang XD, Ye LL, et al. Efficacy and safety of botulinum toxin type A injection in patients with bilateral trapezius hypertrophy. Aesthetic Plast Surg 2018;42:1664–71.
Supornpun N, Rummaneethorn P, Nararatwanchai T, Saiwichai T, et al. Incobotulinum toxin A with a one-year long-lasting effect for trapezius contouring and superior efficacy for the treatment of trapezius myalgia. J Cutan Aesthet Surg 2022;15:168–74.
Yi KH, Lee HJ, Choi YJ, Lee JH, et al. Intramuscular neural distribution of rhomboid muscles: evaluation for botulinum toxin injection using modified Sihler's method. Toxins (Basel) 2020;12:289.
Benítez PA. Onabotulinumtoxin A for correcting trapezius muscle hypertrophy in Asian women. J Cosmet Dermatol 2022;21:2677–9.
Torun Bİ, Kendir S, Filgueira L, Shane Tubbs R, et al. Morphological characteristics of the posterior neck muscles and anatomical landmarks for botulinum toxin injections. Surg Radiol Anat 2021;43:1235–42.
Wang L, Li T, Chi Y, Zhang M, et al. Ultrasonographic analysis of trapezius muscle for efficient botulinum toxin type A injection. Aesthetic Plast Surg 2023;47:2029–36.
Yi KH, Lee HJ, Seo KK, Kim HJ. Intramuscular neural arborization of the latissimus dorsi muscle: application of botulinum neurotoxin injection in flap reconstruction. Toxins (Basel) 2022;14:107.
Berköz HÖ, Kozanoğlu E, Aydın A, Özkan S, et al. The effect of botulinum toxin application on latissimus dorsi and teres major muscles in patients with brachial plexus birth palsy: an electron microscopic and clinical study. Ulus Travma Acil Cerrahi Derg 2023;29:493–8.
Figus A, Mazzocchi M, Dessy LA, Curinga G, et al. Treatment of muscular contraction deformities with botulinum toxin type A after latissimus dorsi flap and sub-pectoral implant breast reconstruction. J Plast Reconstr Aesthet Surg 2009;62:869–75.
Han KH, Joo YH, Moon SE, Kim KH. Botulinum toxin A treatment for contouring of the lower leg. J Dermatolog Treat 2006;17:250–4.
Kunimasa Y, Sano K, Nicol C, Barthèlemy J, et al. Is the muscle-tendon architecture of non-athletic Kenyans different from that of Japanese and French males? J Physiol Anthropol 2023;42:9.
Cheng J, Chung HJ, Friedland M, Hsu SH. Botulinum toxin injections for leg contouring in East Asians. Dermatol Surg 2020;46(Suppl 1):S62–70.
Xu X, Liu D, Wu M, Luo L, et al. The effect of calf subcutaneous fat thickness on patient satisfaction after calf contouring with botulinum toxin A. Plast Reconstr Surg 2024;154:63e–9e.
Tsai SW, Tung YT, Chen HL, Shen CJ, et al. Treadmill running upregulates the expression of acetylcholine receptor in rat gastrocnemius following botulinum toxin A injection. J Orthop Res 2013;31:125–31.
Chong Y, Li Z, Zhang D, Jin L, et al. Ultrasonographic analysis of the calves for efficient botulinum toxin type A injection. J Cosmet Dermatol 2022;21:4301–6.
Zhang Z, Wei Q, Li Y, Zhuang J, et al. Botulinum toxin A injection for hemihypertrophy-related unilateral gastrocnemius hypertrophy. Plast Reconstr Surg Glob Open 2023;11:e5356.
Suh Y, Jeong GJ, Noh H, Sun S, et al. A multicenter, randomized, open-label comparative study of prabotulinumtoxinA with two different dosages and diverse proportional injection styles for the reduction of gastrocnemius muscle hypertrophy in Asian women. Dermatol Ther 2019;32:e13009.
Lee HJ, Lee DW, Park YH, Cha MK, et al. Botulinum toxin a for aesthetic contouring of enlarged medial gastrocnemius muscle. Dermatol Surg 2004;30:867–71.
Wanitphakdeedecha R, Ungaksornpairote C, Kaewkes A, Sathaworawong A, et al. A pilot study comparing the efficacy of two formulations of botulinum toxin type A for muscular calves contouring. J Cosmet Dermatol 2018;17:984–90.
Bogari M, Tan A, Xin Y, Chai G, et al. Treatment of gastrocnemius muscle hypertrophy with botulinum toxin injection followed by magnetic resonance imaging assessment and 3-dimensional evaluation. Aesthet Surg J 2017;37:1146–56.
Wang X, Li X, Yu M. Pulmonary embolism after botulinum toxin treatment for leg muscle hypertrophy. Plast Reconstr Surg Glob Open 2024;12:e5594.
Warner SW, Sanford DA, Becker BA, Bain SD, et al. Botox induced muscle paralysis rapidly degrades bone. Bone 2006;38:257–64.